LIPANTIL

This brand name is authorized in Ireland, Malta, United Kingdom

Active ingredients

The drug LIPANTIL contains one active pharmaceutical ingredient (API):

1 Fenofibrate UNII U202363UOS - FENOFIBRATE

Fenofibrate is a fibric acid derivative whose lipid modifying effects reported in humans are mediated via activation of Peroxisome Proliferator Activated Receptor type α (PPARα). Through activation of PPARα, fenofibrate increases lipolysis and elimination of atherogenic triglyceride rich particles from plasma by activating lipoprotein lipase and reducing production of Apoprotein C-III. Read about Fenofibrate

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LIPANTIL Capsule	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C10AB05	Fenofibrate	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AB Fibrates
Discover more medicines within C10AB05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 143065, 161991, 175682, 184927, 29526, 29572, 29581, 381464, 381465, 381466
Country: IE	Health Products Regulatory Authority	Identifier(s): 31605, 31608, 31620, 31657, 31669
Country: MT	Medicines Authority	Identifier(s): AA1187/00401, AA565/48801, AA770/11501, AA908/18501